96 results about "Pravastatin" patented technology

A combination of one or more HMG-CoA reductase inhibitors (for example pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with one or more insulin sensitizers (for example troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-[1-(4-2'-pyridylphenyl)ethylideneaminooxy]ethoxy}benzyl)thiazolidine-2,4-dione, 5-{4-(5-methoxy-3-methylimidazo[5,4-b]pyridin-2-ylmethoxy)benzyl}thiazolidine-2,4-dione or its hydrochloride, 5-[4-(6-methoxy-1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, 5-[4-(1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione and 5-[4-(5-hydroxy-1,4,6,7-tetramethylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione) exhibits a synergistic effect and is significantly better at preventing and/or treating arteriosclerosis and/or xanthoma than is either of the components of the combination alone.

The present invention relates to an oral drug delivery system comprising pravastatin or its pharmaceutically acceptable salts such that the system provides enhanced stability in the acidic environment of the stomach and exhibits controlled release of the drug.

According to the invention, there is provided a phosphate derivative of a compound having a secondary hydroxy group. The compound having a secondary hydroxyl group may, for example, be chosen from pravastatin, atorvastatin venlafaxine, their derivatives and mixtures thereof.

The present invention provides a microorganism containing a compactin biosynthesis gene and a gene for conversion of compactin into pravastatin. In a preferred example, said compactin biosynthesis gene is mIcA and/or mIcB and/or mIcC and/or mIcD and/or mIcE and/or mIcF and/or mIcG and/or mIcH and/or mIcR and said gene for conversion of compactin into pravastatin is a hydroxylase gene. Furthermore, the present invention provides a method for producing a compound of interest such as a statin. In a preferred example said statin is pravastatin.

The present invention provides a new type balloon dilation catheter which includes ballon and medication material coated on stent. Said medication material comes from one or two and more than two mixtures of heparin sodium, fiber degrading enzyme, serine proteinase, batroxobin, aspirin, genistein, hirudin and its recombined product, colchicine, sirolimus, biolimus, zotarolimus, tracrolimus, pimecrolimus, simvastatin, atorvastatin, pravastatin, ciclosporin, Anti-CD34, dexamethasone, bleomycin, plicamycin, daunomycin, mitomycin C, actinomycin D, taxol, celastrol, methopterin, 5-fluorouracil, cytarabine and 6-purinethol. The balloon is made of macromolecule nylon material, and the stimulation to blood vessel is far lower than the stent with metal structure.

The present invention relates to a new microbial process for the preparation of the compound formula (I)from a compound of general formula (II)wherein R stands for an alkali metal or ammonium ion, by the submerged cultivation of a mold strain able to 6beta-hydroxylate a compound of the Formula (II) in aerobic fermentation and by the separation and purification of the product of Formula (I) formed in the course of the bioconversion. The process comprises cultivating a strain of Mortierella maculata filamentous mold species that is able to 6beta-hydroxylate a compound of the general Formula (II), on a nutrient medium containing assimilable carbon and nitrogen sources and mineral salts and separating the product formed from the fermentation broth, then isolating the compound of formula (I) and purifying the same. Novel strains of Mortierella maculata are also disclosed.

Processes for preparing pravastatin, intermediates and pharmaceutically acceptable salts thereof are provided Crystalline forms of pravastatin, intermediates and pharmaceutically acceptable salts thereof are also disclosed.

The use of HMG-CoA reductase inhibitors (e.g., statins) to treat glaucoma, control intraocular pressure, preserve the trabecular meshwork, protect against ocular neurodegeneration and/or protect against glaucomatous retinopathy is described. The preferred HMG-CoA reductase inhibitors, which are statins having an RI value of 0.2 to 0.7 (e.g., pravastatin), are administered via topical application to the affected eye(s) of the patient.

The invention discloses a fermentation process for producing pravastatin by transforming compactin by using actinomadura yumaense. According to the fermentation process based on the conventional fermentation process, the transformation ability of the microbial substrate and the fermentation level of the pravastatin are improved by adding trace element solution into a fermentation culture medium and utilizing the effect of the trace elements completely; the transformation ability of the microbial transformation bacteria-actinomadura yumaense on the compactin and the fermentation level of the pravastatin are effectively improved by controlling the culture temperature of the actinomadura yumaense and the transformation temperature of the compactin by using actinomadura yumaense; and the fermentation level is far higher than that of the prior art. The fermentation process is simple and convenient to operate, low in cost and suitable for large-scale production.

The present invention provides methods for purification of pravastatin or a pharmacologically acceptable salt thereof using a salting-out technique. Inorganic salts are added to an aqueous solution of pravastatin of a pharmacologically acceptable salt thereof which was obtained from culturing of microorganisms, to selectively precipitate the pravastatin or pharmacologically acceptable salt.

Compositions having excellent blood lipid peroxide lowering activity are provided. In particular, compositions for lowering lipid peroxides in the blood which contain pravastatin together with at least one substance selected from the group consisting of taurine, pantethine and inositol hexanicotinate. Use of these compositions enables the provision of excellent preventive or remedial agents capable of lowering the concentration of lipid peroxides in the blood which show effects of injuring vascular endothelial cells, accelerating platelet aggregation, forming foam cells, etc.

The invention relates to the field of pharmaceutical preparation, in particular to a steady pravastatin medicine composition and a preparation method thereof. The method is characterized in that the stability of the pravastatin medicine composition is remarkably improved by adding a certain amount of meglumine. A high-destructive experiment and long-term storage show that the pravastatin medicine composition has a tiny lactone degradation product.

The invention provides a method for treating hyperviscosemia, in particular the use of statins antihyperglycemic medicaments and aspirin in preparing medicament for the treatment of hyperviscosemia, wherein the content of aspirin is 25-250mg, the statins antihyperglycemic medicament is selected from simvastatin, pravastatin, lovastatin, fluvastatin, atorvastatin, rosuvastatin and pitavastatin.

The present invention relates to a new microbial process for the preparation of compound formula (I) from a compound of general formula (II) wherein R stands for an alkali metal or ammonium ion, by the submerged cultivation of a mold strain able to 6 beta -hydroxylate a compound of Formula (II) in aerobic fermentation and by the separation and purification of the product of Formula (I) formed in the course of the bioconversion. The process comprises cultivating a strain of Mortierella maculata filamentous mold species that is able to 6 beta -hydroxylate a compound of general Formula (II), on a nutrient medium containing assimilable carbon and nitrogen sources and mineral salts and separating the product formed from the fermentation broth, then isolating the compound of formula (I) and purifying the same. Novel strains of Mortierella maculata are also disclosed.

A pharmaceutical combination for sensitizing a subject to a cancer treatment comprises an amount of metformin and an amount of statin. The amount of metformin and the amount of statin together constitute an effective amount of the pharmaceutical combination. The statin is selected from a group consisting of atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin. The cancer treatment is preferably a radiotherapy. The pharmaceutical combination may be included in a pharmaceutical composition. A method of treating cancer is also provided. The method comprises administering the pharmaceutical combination to a subject and delivering an effective dose of radiation to the subject.

A controlled Release Pharmaceutical composition comprising an effective amount of Pravastatin and Fenofibrate, characterised in that the difference, in absolute value, between the times of maximal concentration (T_max) of Pravastatin and Fenofibric acid is not less than 1.5 hours upon administration with food to humans.

The present invention provides a polypeptide having an amino acid sequence according to SEQ ID NO 3, SEQ ID NO 6 or SEQ ID NO 43-59. The present invention also provides a polynucleotide comprising a DNA sequence encoding these polypeptides and a method for isolating polynucleotides encoding polypeptides capable of improving the compactin into pravastatin conversion. Furthermore, the present invention provides a method for producing pravastatin and a pharmaceutical composition comprising pravastatin.